While frequent urination is not listed as a direct side effect in FDA prescribing information, some patients report changes in urinary patterns
Clinical and Real-World Evidence of GLP-1s on Cravings Studies show reduced hunger and calorie intake, but craving-related effects are based on early research and patient reports rather than confirmed clinical trials
( PMID: 23324757 ) Benzaquen M, Borradori L, Berbis P, Cazzaniga S, Valero R, Richard MA, Feldmeyer L (2018) Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: retrospective multicenter case-control study from France and Switzerland
Semaglutide GLP-1 injections have been shown to reduce the risk of major cardiovascular events, such as heart attack and stroke, in people with type 2 diabetes
Elevated resting heart rate is an independent risk factor for adverse outcomes in heart failure, and beta-blocker therapy to reduce heart rate is a cornerstone of HFrEF management
GLP-1RAs have been combined with glucose-dependent insulinotropic agonism, as well as glucagon agonism or amylin analogues to further enhance their metabolic benefits
